Sector
PharmaceuticalsOpen
₹2,384.3Prev. Close
₹2,393.7Turnover(Lac.)
₹22,192.25Day's High
₹2,430Day's Low
₹2,36052 Week's High
₹2,47452 Week's Low
₹1,355.4Book Value
₹863.82Face Value
₹1Mkt Cap (₹ Cr.)
68,233.33P/E
45.51EPS
52.57Divi. Yield
0.122 Aug 2025
12:00 AM
AGM
Announcement Date: 22 Aug, 2025
22 Aug 2025
12:00 AM
BookCloser
19 Jan 2026
12:00 AM
Board Meeting
Agenda : Audited Result
26 Sep 2025
12:00 AM
Dividend
Dividend Amount: 2.5
Record Date: 03 Oct, 2025
Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.
Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.
At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.
Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,475.74 | 22,942.4 | 17,849.25 | 16,710.37 |
Net Worth | 24,503.96 | 22,970.62 | 17,877.47 | 16,738.59 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 7,567.93 | 6,712.63 | 6,403.23 | 7,989.23 |
yoy growth (%) | 12.74 | 4.83 | -19.85 | 30.64 |
Raw materials | -2,999.45 | -2,665.99 | -2,378.59 | -2,425.49 |
As % of sales | 39.63 | 39.71 | 37.14 | 30.35 |
Employee costs | -1,107.39 | -1,072.32 | -1,021.92 | -914.47 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,869.86 | 1,516.09 | 1,218.82 | 2,789.34 |
Depreciation | -150.81 | -138.53 | -118.2 | -104.93 |
Tax paid | -294.31 | -180.09 | -204.47 | -412.28 |
Working capital | 463.74 | -1,507.52 | -180.36 | 1,492.86 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.74 | 4.83 | -19.85 | 30.64 |
Op profit growth | 44.93 | -3.21 | -53.51 | 64.2 |
EBIT growth | 20.49 | 25.73 | -52.08 | 65.02 |
Net profit growth | 21.77 | 33.53 | -52.61 | 44.21 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Other Operating Income | 175.9 | 177.64 | 151.3 | 130.71 | 137.9 |
Other Income | 113.72 | 1,237.32 | 755.86 | 166.67 | 94.76 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,820.8 | 100.1 | 4,36,858.91 | 705.44 | 0.88 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,651 | 68.65 | 1,76,617.57 | 598 | 0.45 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,275.1 | 64.8 | 1,44,717.58 | 577 | 0.14 | 2,547 | 249.82 |
Cipla Ltd CIPLA | 1,333.7 | 23.51 | 1,07,721.85 | 616.88 | 1.2 | 4,256.93 | 411.55 |
Lupin Ltd LUPIN | 2,343.3 | 19.38 | 1,07,143.97 | 717.45 | 0.51 | 4,433.96 | 595.44 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Glenn Saldanha
ED / WTD / Promoter
Cheryl Pinto
ED / President / Global CFO
Anurag Mantri
Non Executive Director
B E Saldanha
Independent Non Exe. Director
Sona Saira Ramasastry
Independent Non Exe. Director
Dipankar Bhattacharjee
Independent Non Exe. Director
V R Iyer
Independent Non Exe. Director
Pradeep Kumar Sinha
Company Sec. & Compli. Officer
Harish Kuber
B/2 Mahalaxmi Chambers,
22 Bhulabhai Desai Road,
Maharashtra - 400026
Tel: 91-22-40189999
Website: http://www.glenmarkpharma.com
Email: complianceofficer@glenmarkpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological enti...
Read More
Reports by Glenmark Pharmaceuticals Ltd
What is the Glenmark Pharmaceuticals Ltd share price today?
What is the Market Cap of Glenmark Pharmaceuticals Ltd?
What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?
What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?
What is the CAGR of Glenmark Pharmaceuticals Ltd?
What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Reg. No. INM000010940, SEBI RA Regn. No: INH000000248, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
